Scotland Archives -

NICE verdict on Trodelvy threatens unequal access to drug in UK

Phil Taylor access, England, Gilead Sciences, HEOR, NHS, NICE, Scotland, Trodelvy 0 Comment

In draft guidance, NICE has said it cannot recommend Gilead Sciences’ Trodelvy in triple-negative breast cancer (TNBC), setting

NICE verdict on Trodelvy threatens unequal access to drug in UK

https://pharmaphorum.com/news/nice-verdict-on-trodelvy-threatens-unequal-access-to-drug-in-uk/

Digital/ News/ News

Digital therapeutics world first for Big Health in Scotland

Dominic Tyer anxiety, Big Health, digital health, digital therapeutics, insomnia, NHS, Scotland 0 Comment

UK-based Big Health has passed a digital health milestone after Scotland became the first country to make anxiety

Digital therapeutics world first for Big Health in Scotland

https://pharmaphorum.com/news/digital-therapeutics-world-first-big-health-scotland/

Market Access/ Oncology/ Views & Analysis/ Views & Analysis/ Views and analysis

Collaborate to simplify cancer trials and accelerate post-pandemic recovery

Amanda Barrell ABPI, cancer care, NHS, Scotland 0 Comment

How could simplifying the administration of clinical trials help cancer diagnosis, care, and treatment levels to exceed pre-pandemic

Collaborate to simplify cancer trials and accelerate post-pandemic recovery

https://pharmaphorum.com/views-and-analysis/collaborate-to-simplify-cancer-trials-and-accelerate-post-pandemic-recovery/

Market Access/ News/ News

Scotland backs Bavencio for bladder cancer after NICE says no

Phil Taylor Bavencio, bladder cancer, Merck KGaA, NHS, NICE, Pfizer, Scotland, Scottish Medicines Consortium, urothelial carcinoma 0 Comment

Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance

Scotland backs Bavencio for bladder cancer after NICE says no

https://pharmaphorum.com/news/scotland-backs-bavencio-for-bladder-cancer-after-nice-says-no/

Market Access/ News/ News

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

Phil Taylor AstraZeneca, Boehringer Ingelheim, Calquence, Eli Lilly, Kyowa Kirin, NHS, nintedanib, Olumiant, Oncology, Poteligeo, Scotland, Scottish Medicines Consortium, Servier 0 Comment

A north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s

Scotland backs rare blood cancer drug Poteligeo rejected by NICE

https://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/

Market Access/ News/ News

Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

Phil Taylor Alexion, AstraZeneca, Health Technology Assessment, HEOR, nephrology, NHS, rare disease, Scotland, Soliris, Ultomiris 0 Comment

NHS patients in Scotland with the rare disease atypical haemolytic uremic syndrome (aHUS) will now be able to

Scotland backs NHS use of Alexion’s Ultomiris for rare disease aHUS

https://pharmaphorum.com/news/scotland-backs-nhs-use-of-alexions-ultomiris-for-rare-disease-ahus/

Young man in a wheelchair looking at the nature

Market Access/ News/ News

Scotland opens door to Translarna for Duchenne muscular dystrophy

Phil Taylor asthma, Duchenne muscular dystrophy, Dupixent, HEOR, PTC Therapeutics, rare disease, Regeneron, Sanofi, Scotland, Translarna 0 Comment

A disparity in UK access to a medicine for Duchenne muscular dystrophy (DMD) has been addressed, after Scotland

Scotland opens door to Translarna for Duchenne muscular dystrophy

https://pharmaphorum.com/news/scotland-opens-door-to-translarna-for-duchenne-muscular-dystrophy/

News

Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensma

Phil Taylor HEOR, NHS, Novartis, Roche, Rozlytrek, Scotland, Scottish Medicines Consortium, Zolgensma 0 Comment

The Scottish Medicines Consortium (SMC) has said Roche’s Rozlytrek can be used by NHS Scotland for the treatment

Double first for Scotland as it backs Roche’s Rozlytrek, Novartis’ Zolgensma

https://pharmaphorum.com/news/double-first-for-scotland-as-it-backs-roches-rozlytrek-novartis-zolgensma/

Market Access/ Views & Analysis/ Views and analysis

How does HTA for orphan drugs differ across Europe?

George Underwood England, Europe, France, Germany, HTA, NICE, orphan drugs, Rare diseases, Scotland, SMC, UK 0 Comment

New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines

How does HTA for orphan drugs differ across Europe?

https://pharmaphorum.com/views-analysis-market-access/how-does-hta-for-orphan-drugs-differ-across-europe/

Trending

Scotland

Login